Adam S. Lazorchak
Biogen (United States)(US)Sarepta Therapeutics (United States)(US)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, PI3K/AKT/mTOR signaling in cancer, Ferroptosis and cancer prognosis, CAR-T cell therapy research, Advanced Breast Cancer Therapies
Most-Cited Works
- → The mammalian target of rapamycin complex 2 controls folding and stability of Akt and protein kinase C(2008)509 cited
- → Sin1 phosphorylation impairs mTORC2 complex integrity and inhibits downstream Akt signalling to suppress tumorigenesis(2013)254 cited
- → Simultaneous targeting of TGF-β/PD-L1 synergizes with radiotherapy by reprogramming the tumor microenvironment to overcome immune evasion(2021)183 cited
- → Human ESC-Derived MSCs Outperform Bone Marrow MSCs in the Treatment of an EAE Model of Multiple Sclerosis(2014)166 cited
- → Immune modulatory mesenchymal stem cells derived from human embryonic stem cells through a trophoblast-like stage(2015)80 cited
- → mTOR Complex 2 Targets Akt for Proteasomal Degradation via Phosphorylation at the Hydrophobic Motif(2011)76 cited
- → Sin1-mTORC2 Suppresses rag and il7r Gene Expression through Akt2 in B Cells(2010)69 cited
- → E2A and IRF-4/Pip Promote Chromatin Modification and Transcription of the Immunoglobulin κ Locus in Pre-B Cells(2006)66 cited
- → CA-170, a first in class oral small molecule dual inhibitor of immune checkpoints PD-L1 and VISTA, demonstrates tumor growth inhibition in pre-clinical models and promotes T cell activation in Phase 1 study(2017)55 cited
- → New insights into E-protein function in lymphocyte development(2005)50 cited